TY - JOUR
T1 - 1998 update on antiphospholipid antibodies
AU - Petri, Michelle
PY - 1998
Y1 - 1998
N2 - The field of antiphospholipid antibodies continues to evolve, with major contributions from both clinical research and laboratory studies. Antiphospholipid antibodies remain one of the more common causes of acquired hypercoagulability, both in patients with systemic lupus erythematosus and in patients who have no known connective tissue disease. In recent years, great progress has been made in identifying the protein targets. In addition, knowledge of the clinical syndrome that we call antiphospholipid antibody syndrome has also progressed. Finally, new insights into treatment continue to be gained from clinical trials.
AB - The field of antiphospholipid antibodies continues to evolve, with major contributions from both clinical research and laboratory studies. Antiphospholipid antibodies remain one of the more common causes of acquired hypercoagulability, both in patients with systemic lupus erythematosus and in patients who have no known connective tissue disease. In recent years, great progress has been made in identifying the protein targets. In addition, knowledge of the clinical syndrome that we call antiphospholipid antibody syndrome has also progressed. Finally, new insights into treatment continue to be gained from clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=0031719133&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031719133&partnerID=8YFLogxK
U2 - 10.1097/00002281-199809000-00005
DO - 10.1097/00002281-199809000-00005
M3 - Short survey
C2 - 9746857
AN - SCOPUS:0031719133
SN - 1040-8711
VL - 10
SP - 426
EP - 430
JO - Current Opinion in Rheumatology
JF - Current Opinion in Rheumatology
IS - 5
ER -